Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
4, 4'-methylene bis (2-chloroaniline) (MOCA) is a Group 1 carcinogen for which a role of the NAT2 acetylation polymorphism on cancer risk is unknown.
|
29180287 |
2018 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic polymorphisms of NAT2 modify drug efficacy and toxicity and susceptibility to diseases such as cancer and type 2 diabetes.
|
30149019 |
2018 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results further support phenotypic heterogeneity among NAT2 slow acetylator genotypes, consistent with differential risks of drug failure or toxicity and cancer associated with carcinogen exposure.
|
28516247 |
2017 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic polymorphism in NAT2 modifies drug efficacy and toxicity as well as cancer risk.
|
28523442 |
2017 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Daily ingestion of peppermint tea may alter pharmacokinetics of clinically administered drugs and promote cancer chemoprevention through NAT2 inhibition.
|
28011360 |
2017 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In a case-only analysis, frequent red meat consumption was associated with a significantly increased cancer risk for NAT2 slow/intermediate acetylators in the Mixed Ancestry population (OR = 3.55; 95% CI 1.29-9.82; P = 0.019), whereas daily white meat intake was associated with an increased risk among NAT1 slow/intermediate acetylators in the Black population (OR = 1.82; 95% CI 1.09-3.04; P = 0.023).
|
25886288 |
2015 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The incidence of bladder cancer is closely associated with exposure to aromatic amines, that can cause cancer only after metabolic activation regulated by N-acetyl transferase 1 and 2 (NAT1 and NAT2).
|
26681036 |
2015 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The NAT2 rs1799930 (G590A) may change drug-induced toxicity and affect cancer susceptibility.
|
25005845 |
2014 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Polymorphism in NAT2 gene is reported to be associated with susceptibility to various types of cancer.
|
24816842 |
2014 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Numerous studies have analyzed the impact of N-acetyltransferase 2 (NAT2) polymorphisms on drug efficacy, side effects as well as cancer risk.
|
24524665 |
2014 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In contrast, a significant association was observed between the NAT2 rs1799931 G>A polymorphism and decreased cancer susceptibility in overall meta-analysis (AA vs. GG: OR=0.55, 95% CI=0.33-0.93; GA vs. GG: OR=1.00, 95% CI=0.88-1.14; dominant model: OR=0.97, 95% CI=0.86-1.10; recessive model: OR=0.56, 95% CI=0.34-0.94) and the Asian group (AA vs. GG: OR=0.50, 95% CI=0.26-0.94; recessive model, OR=0.50, 95% CI=0.27-0.94).
|
25081676 |
2014 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To evaluate associations between polymorphisms of the N-acetyltransferase 2 (NAT2), human 8-oxoguanine glycosylase 1 (hOGG1) and X-ray repair cross-complementing protein 1 (XRCC1) genes and risk of upper aerodigestive tract (UADT) cancer.
|
24922697 |
2014 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated the association between NAT2 slow acetylation and bladder cancer in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition.
|
24092628 |
2013 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An adenine (A) to guanine (G) single nucleotide polymorphism at position 61 in the 5'-untranslated region (5'-UTR) of the EGF gene has been found to be associated with levels of EGF production, and the mutations in the NAT2 gene have been postulated as a risk factor for cancer.
|
22782629 |
2012 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We undertook this study to check whether polymorphisms at NAT1 can modulate the risk of oral leukoplakia and cancer either alone or in combination with NAT2.
|
23168701 |
2012 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This enzyme is genetically variable in human populations and polymorphisms in the NAT2 gene have been associated with drug toxicity and efficacy as well as cancer susceptibility.
|
19909761 |
2010 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our observations could be useful in assessing the susceptibility of different populations to cancer and contribute to better predictions of the pharmacokinetics and pharmacodynamics of drugs that are metabolized by NAT2, in different populations.
|
20175805 |
2009 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The results do not suggest a different distribution of GSTM1 and NAT2 polymorphisms in the studied population compared to those reported for other Caucasian populations and warrant further studies in order to evaluate their potential relationship with individual cancer risks.
|
19443391 |
2009 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Gene-gene interaction testing suggested several cancer-NAT2 associations, with association strongest among persons without a CYP1A1 variant (*2C or *4) allele (OR 1.77, 95% CI 1.20-2.60, p value = .03) or with a variant MPO (463A) allele (OR 2.38, 95% CI 1.34-4.21, p value = .05).
|
18642288 |
2008 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
As genotyping procedures have become available for NAT1 and NAT2 gene variations, hundreds of association studies on NAT polymorphisms and cancer risk have been conducted.
|
18680472 |
2008 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We hypothesized that NAT1 and/or NAT2 polymorphisms contribute to the increased cancer evident in IBD.
|
17537267 |
2007 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The NAT2 2*6 and 2*7 allele frequencies were higher in GBC and conferred significant risk of cancer (OR 1.9, 95% Cl = 1.2-2.9, p= 0.006; OR, 2.9, 95% Cl = 1.6-5.2, p = 0.0001).
|
17224641 |
2007 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
But, tobacco users carrying susceptible NAT2 and DNA repair loci might be at risk of oral leukoplakia and cancer.
|
17290401 |
2007 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The frequencies of seven NAT2 point mutations, namely G191A, C282T, T341C, C481T, G590A, A803G, and G857A, and genotypes were determined by PCR/RFLP in a total of 70 patients with allergic contact dermatitis to PPD and 100 control subjects with no history of allergy, atopy, lung disease, diabetes mellitus and cancer.
|
16533241 |
2006 |
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The NAT2 fast acetylator and EPHX1 low-activity genotypes were positively associated with MM in the Italian study, while they were negatively associated with this malignancy in the Finnish one.
|
16697254 |
2006 |